Santhera Pharmaceuticals Holding AG (0QN1) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to the Santhera Pharmaceuticals Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and could be submitted at any time via the Q and A tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand you over to the management team. Dorio, good morning, sir. Thank you, Lily. Good morning for those in The US who are joining us, and good afternoon for those in here in Europe, and welcome to this full year twenty twenty five investor call. As usual, I'm today joined by Catherine Eisted, who is our Chief Financial Officer, as well as Shabir Hasham, who is our Chief Medical Officer. They will both give their respective parts of the presentation and be here for the Q and A as well. So can I have the next slide please? Can we have the next slide after that? Here we go. No, the disclaimer please. Can we go back? So I just want to draw your attention to the greetings from our legal department here where you should at your own leisure read this if you're not familiar with the text. And with that, let's move into the actual presentation. So 2025 was a real exciting year with expansion and global momentum continuing. These six points that you can see on this slide here really are the summary of our presentation today. We will have deeper dives on each of the six subjects, but I just want to highlight a few things here that first of all in Austria and Germa...